Post-Transplant Cyclophosphamide in Hematopoietic Stem Cell Transplantation for Langerhans Cell Histiocytosis: OAJBS Publishers
Post-Transplant Cyclophosphamide in Hematopoietic Stem Cell Transplantation for Langerhans Cell Histiocytosis by Rong Liu in Open Access Journal of Biomedical Science
Hematopoietic
stem cell transplantation (HSCT) has the potential to cure refractory
multisystem Langerhans cell histiocytosis (MS-LCH). However, a post-transplant
cyclophosphamide (PTCy) regimen has never been applied for refractory MS-LCH.
The objective of this article is to report the successful use of PTCy after
reduced-intensity conditioning haploid HSCT in a 22-monthold girl with
refractory MS-LCH and hemophagocytic lymphohistiocytosis (HLH). Her clinical
symptoms were recurrent fever, polydipsia, diuresis, rash, and
hepatosplenomegaly. She failed to respond to chemotherapy but was finally cured
by haploid HSCT with PTCy regime. This case enriched our knowledge of the
management of graft-versus-host disease prophylaxis in LCH patients, which has
not been reported before.
https://biomedscis.com/fulltext/post-transplant-cyclophosphamide-in-hematopoietic-stem-cell-transplantation-for-langerhans-cell-histiocytosis.ID.000214.php
To
Know More About Open Access Journal of
Biomedical Science Please Visit: Biomedscis
Are
Click On: https://Biomedscis.Com/
Comments
Post a Comment